Company Filing History:
2 out of 18 
1 out of 592 Years Active: 2020-2025
Title: Innovations of Inventor Tae Young Yune in Antibody Development
Introduction: Tae Young Yune, an accomplished inventor based in Seoul, South Korea, has made significant contributions to the field of biotechnology. With a total of three patents to his name, Yune's work primarily revolves around innovative antibody treatments targeting specific human proteins. His research aims to address critical health challenges, particularly in the realm of neurodegenerative disorders and pain management.
Latest Patents: Among Tae Young Yune's notable patents is the invention related to “Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof.” This patent encompasses the development of antibodies that bind specifically to human FAM19A5. The antibodies created in this framework can modulate FAM19A5 activity, potentially inhibiting, suppressing, or reversing the onset of reactive gliosis and excessive proliferation of reactive astrocytes. Additionally, the patent details methods for treating various disorders, such as central nervous system damage, degenerative brain disorders, and neuropathic pain, through the administration of these specialized antibodies.
Career Highlights: Tae Young Yune has cultivated a career characterized by innovation and collaboration in the biotechnology sector. He has worked with renowned organizations such as Neuracle Science Co., Ltd. and the University-industry Cooperation Group of Kyung Hee University. His efforts have significantly advanced the understanding and application of therapeutic antibodies in medical science.
Collaborations: Throughout his career, Yune has collaborated with esteemed colleagues like Jee Youn Lee and Bongcheol Kim. Their cooperation has led to fruitful developments in his research and has furthered the field of biotechnology through shared knowledge and expertise.
Conclusion: Inventor Tae Young Yune stands out as a pivotal figure in the development of antibody therapies targeting human FAM19A5. His three patents reflect a commitment to addressing complex medical challenges, particularly in neurodegenerative conditions. As he continues to push the boundaries of innovation, the impact of his work is likely to resonate in the biomedical community and beyond.